Daratumumab/Carfilzomib/Dexamethasone for Multiple Myeloma: Meletios A. Dimopoulos, MD

Recently, the FDA approved a new treatment for multiple myeloma previously treated with one to three lines of therapy: daratumumab (Darzalex®, Janssen) in combination with carfilzomib and dexamethasone. In this interview, Meletios Dimopoulos, MD, principal investigator of the phase 3 CANDOR trial, which served as the basis for the approval, speaks with i3 Health regarding the benefits and adverse events of this new therapeutic combination, as well as additional advances in the treatment of relap...
Continue reading

New Daratumumab Combination Approved for Multiple Myeloma

The FDA has approved a new therapeutic combination involving daratumumab (Darzalex®, Janssen), carfilzomib, and dexamethasone for the treatment of adults with multiple myeloma previously treated with one to three lines of therapy. Daratumumab, the first CD37 monoclonal antibody to reach the market, has previously been approved for multiple myeloma in combination with bortezomib/thalidomide/dexamethasone for transplant-eligible newly diagnosed patients, in combination with lenalidomide/dexamethas...
Continue reading

Multiple Myeloma: Adding Daratumumab to Carfilzomib/Dexamethasone Enhances Efficacy

Results from the phase 3 CANDOR trial show that for relapsed/refractory multiple myeloma, adding daratumumab (D) to carfilzomib/dexamethasone (Kd) increases efficacy compared with Kd alone. "Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relapsed or refractory multiple myeloma," write the study investigators in their publication in The Lancet, led by Meletios Dimopoulos, MD, Professor and Chairman of Clinical Therapeutics at the Na...
Continue reading

Daratumumab and Hyaluronidase-fihj FDA Approved for Multiple Myeloma

Daratumumab and hyaluronidase-fihj (Darzalex Faspro™, Janssen Biotech, Inc.) has been approved by the FDA and allows for subcutaneous dosing of daratumumab for adult patients with newly diagnosed or relapsed/refractory multiple myeloma. Previously, intravenous daratumumab was approved for the following indications for patients with multiple myeloma: in combination with bortezomib, melphalan, and prednisone, in combination with lenalidomide and dexamethasone, in combination with bortezomib and de...
Continue reading

Adding Daratumumab to VMP for Transplant-Ineligible Myeloma: Maria Victoria Mateos, MD, PhD

Over half of patients with newly diagnosed multiple myeloma (NDMM) are ineligible for autologous stem cell transplantation. For these patients, a combination therapy consisting of the proteasome inhibitor bortezomib with melphalan and prednisone is one of the preferred treatments. Adding daratumumab to standard regimens for transplant-ineligible NDMM and relapsed/refractory multiple myeloma has had promising results. Now, data from the phase 3 ALCYONE trial show that adding daratumumab to bortez...
Continue reading

Copyright © 2020 Oncology Data Advisor. All rights reserved.